Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10004)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2014 (publication date) through Apr 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol 2014; 20(41): 15269-15274 [PMID: 25386075 DOI: 10.3748/wjg.v20.i41.15269] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i41/15269.htm |
| Number | Citing Articles |
| 1 |
Dong-Mei Wu, Zi-Hui Zheng, Ying-Bo Zhang, Shao-Hua Fan, Zi-Feng Zhang, Yong-Jian Wang, Yuan-Lin Zheng, Jun Lu. RETRACTED ARTICLE: Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1239-3
|
| 2 |
Nahla E. El-Ashmawy, Eman G. Khedr, Hoda A. El-Bahrawy, Eslam E. Abd El-Fattah. Effect of Pomegranate Hull Extract on Liver Neoplastic Changes in Rats: More than an Antioxidant. Nutrition and Cancer 2016; 68(6): 1044 doi: 10.1080/01635581.2016.1192205
|
| 3 |
Ioannis A Ziogas, Georgios Tsoulfas. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World Journal of Clinical Oncology 2017; 8(3): 203-213 doi: 10.5306/wjco.v8.i3.203
|
| 4 |
Inès Dufait, Els Van Valckenborgh, Eline Menu, David Escors, Mark De Ridder, Karine Breckpot. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget 2106; 7(27): 42698 doi: 10.18632/oncotarget.8311
|
| 5 |
Ruyin Chen, Qiong Li, Shuaishuai Xu, Chanqi Ye, Tian Tian, Qi Jiang, Jianzhen Shan, Jian Ruan. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell International 2022; 22(1) doi: 10.1186/s12935-021-02435-4
|
| 6 |
Timothy J. Stuhlmiller, Jon S. Zawistowski, Xin Chen, Noah Sciaky, Steven P. Angus, Sean T. Hicks, Traci L. Parry, Wei Huang, Ju Youn Beak, Monte S. Willis, Gary L. Johnson, Brian C. Jensen. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association 2017; 6(10) doi: 10.1161/JAHA.117.006635
|
| 7 |
Huma Rafiq, Junjian Hu, Mohammed Ageeli Hakami, Ali Hazazi, Mubarak A. Alamri, Hind A. Alkhatabi, Arif Mahmood, Bader S. Alotaibi, Abdul Wadood, Xiaoyun Huang. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-46193-x
|
| 8 |
Sukant Garg, Sunil Kaul, Renu Wadhwa. Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review). International Journal of Oncology 2017; doi: 10.3892/ijo.2017.4203
|
| 9 |
Wei Hu, Jianjun Lv, Mengzhen Han, Zhi Yang, Tian Li, Shuai Jiang, Yang Yang. STAT3: The art of multi-tasking of metabolic and immune functions in obesity. Progress in Lipid Research 2018; 70: 17 doi: 10.1016/j.plipres.2018.04.002
|
| 10 |
Yonghua Lin, Baoyan Zhang, Linfeng Su, Jianfeng Wei, Zhichao Chen, Min Wu. Expression of lncRNA DLX6-AS1 in patients with hepatic carcinoma and its prognostic value. Biotechnology and Genetic Engineering Reviews 2024; 40(4): 3976 doi: 10.1080/02648725.2023.2204706
|
| 11 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 167 doi: 10.1016/B978-0-12-809400-6.00008-1
|
| 12 |
Lili Chen, Bowen Jiang, Chunge Zhong, Jun Guo, Lihao Zhang, Teng Mu, Qiuhua Zhang, Xiuli Bi. Chemoprevention of colorectal cancer by black raspberry anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation. Carcinogenesis 2018; 39(3): 471 doi: 10.1093/carcin/bgy009
|
| 13 |
Youming Ding, Xiaoyan Chen, Bin Wang, Bin Yu, Jianhui Ge. Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in hepatocellular carcinoma cells. European Journal of Pharmacology 2018; 825: 10 doi: 10.1016/j.ejphar.2018.02.020
|
| 14 |
Yukari Mizukami, Koji Sugawara, Yukimi Kira, Daisuke Tsuruta. Sorafenib stimulates human skin type mast cell degranulation and maturation. Journal of Dermatological Science 2017; 88(3): 308 doi: 10.1016/j.jdermsci.2017.08.005
|
| 15 |
Yide Huang, Yafei Zhang, Lilin Ge, Yao Lin, Hang Kwok. The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma. Cancers 2018; 10(3): 82 doi: 10.3390/cancers10030082
|
| 16 |
You-Li Xie, Wen-Hui Tao, Ti-Xiong Yang, Jian-Guo Qiao. Anticancer effect of cucurbitacin B on MKN-45 cells via inhibition of the JAK2/STAT3 signaling pathway. Experimental and Therapeutic Medicine 2016; 12(4): 2709 doi: 10.3892/etm.2016.3670
|
| 17 |
Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, Richard J. Honeywell, Henk Dekker, Dennis Poel, Kaamar Azijli, Godefridus J. Peters, Henk J. Broxterman, Henk M. W. Verheul. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology 2015; 38(2): 119 doi: 10.1007/s13402-015-0218-8
|
| 18 |
Nahla E. El-Ashmawy, Eman G. Khedr, Hoda A. El-Bahrawy, Eslam E. Abd El-Fattah. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clinical and Experimental Medicine 2017; 17(2): 185 doi: 10.1007/s10238-016-0416-3
|
| 19 |
Jianwei Wei, Zhengfeng Wang, Weiwei Wang, Xiaoge Liu, Junhu Wan, Yongjie Yuan, Xueyuan Li, Liwei Ma, Xianzhi Liu. Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.660005
|
| 20 |
Huimin Liu, Tianxin Du, Chen Li, Guoqing Yang. STAT3 phosphorylation in central leptin resistance. Nutrition & Metabolism 2021; 18(1) doi: 10.1186/s12986-021-00569-w
|
| 21 |
Aliaa M. Mohassab, Heba A. Hassan, Dalia Abdelhamid, Mohamed Abdel-Aziz. STAT3 transcription factor as target for anti-cancer therapy. Pharmacological Reports 2020; 72(5): 1101 doi: 10.1007/s43440-020-00156-5
|
| 22 |
Weijia Zhao, Binglong Bai, Zhong Hong, Xuming Zhang, Bin Zhou. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. ACS Omega 2020; 5(38): 24838 doi: 10.1021/acsomega.0c03527
|
| 23 |
Ji-xiang Zhang. Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy. Medical Science Monitor 2015; 21: 1781 doi: 10.12659/MSM.894669
|
| 24 |
Karine Breckpot. Myeloid-Derived Suppressor Cells and Cancer. SpringerBriefs in Immunology 2016; : 73 doi: 10.1007/978-3-319-26821-7_6
|
| 25 |
Andrea Lazzarini, Antonio Macchiarulo, Alessandro Floridi, Alice Coletti, Samuela Cataldi, Michela Codini, Remo Lazzarini, Elisa Bartoccini, Giacomo Cascianelli, Francesco Saverio Ambesi-Impiombato, Tommaso Beccari, Francesco Curcio, Elisabetta Albi, Patricia Bassereau. Very-long-chain fatty acid sphingomyelin in nuclear lipid microdomains of hepatocytes and hepatoma cells: can the exchange from C24:0 to C16:0 affect signal proteins and vitamin D receptor?. Molecular Biology of the Cell 2015; 26(13): 2418 doi: 10.1091/mbc.e15-04-0229
|
| 26 |
Zhonghao Jiang, Chaoliu Dai. Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib. Journal of Hepatocellular Carcinoma 2023; : 257 doi: 10.2147/JHC.S396231
|